NewLink Genetics (NLNK) Takes Drastic Plunge; Aeterna Zentaris (AEZS) Narrows Loss


Shares of NewLink Genetics Corp. (Nasdaq:NLNK) slumped more than 30% to touch a new 52-week low in after-hours trading Monday as the company said that a Phase 3 trial evaluating its immunotherapy algenpantucel-L in patients with resected pancreatic cancer has failed to meet the primary endpoint.

NLNK stock finished the regular session at $16.50, up $0.95 (or +6.11%) and 1,095,764 of its shares exchanged hands during the day

NewLink Genetics has 28.86M Shares Outstanding. At close on Monday, the biopharmaceutical company had Market Capitalization of $476.21M and NLNK stock one-year range was from $15.15 to $56.16 per share



Aeterna Zentaris Inc. (Nasdaq:AEZS) stock surged $0.06 (or $1.75%) to $3.48, with a total volume of 149,199 shares traded on Monday

After the closing bell, the specialty biopharmaceutical company delivered a significant improvement in its financial results driven by lower operating expenses and higher net finance income compared to the same period the prior year

For the first quarter 2016, Aeterna posted a net loss of ($3.7) million, or ($0.37) per diluted share versus a net loss of ($9.7) million, or ($13.59) per diluted share for the three-month period ended March 31, 2015.

Aeterna Zentaris, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health, has 6.33M Shares Outstanding, Market Capitalization (intraday) of $22.02M and AEZS stock 52-week range is between $2.60 and $51.00 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at